Marco Meglio is an Assistant Managing Editor at NeurologyLive. He focuses on various aspects of medicine and healthcare, including medical specialties, alternative medicine, and innovations in medical technology, while also covering topics such as gene therapy, immunotherapy, and digital health. Marco's work has been featured in Cliggott Publishing Co, Contagion_Live, CGTLive, Patient Care, AJMC - The American Journal of Managed Care, NewsBreak, and HCP Live.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Marco Meglio's coverage primarily focuses on the healthcare and pharmaceutical industry, with a strong emphasis on neurology-related topics such as clinical trials, multiple sclerosis, Parkinson's disease, and Duchenne muscular dystrophy. His articles frequently cite data and press releases.
Given this focus, Marco may be interested in receiving pitches related to ongoing or upcoming clinical trials in the field of neurology and pharmaceuticals. Pitches that offer access to exclusive data or insights from leading experts within these areas would likely resonate well with him.
As he covers a wide range of scientific themes within healthcare and pharmaceuticals, sources should ensure that their pitches are evidence-based and provide valuable contributions to ongoing research or developments in these fields.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Marco Meglio
A phase 1 feasibility trial found that placing GammaTile radiation therapy directly into the surgical cavity during glioblastoma resection sharply reduced rapid early tumor regrowth compared with historical rates, setting up a phase 3 randomized trial.
A case report documented MOG-IgG antibodies in a mother's breast milk following severe MOGAD, though her breastfed infant's serum tested negative.
By: Lorie Richards, Marco Meglio
The chair of the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery discussed the major themes, clinical takeaways, and unanswered questions from the first update to the guideline in a decade.
By: Marco Meglio
The European Commission approved modified-release carbidopa/levodopa capsules, already available in the US as Crexont, for adults with moderate to severe motor fluctuations.
By: Marco Meglio
The updated guideline offers evidence-graded recommendations on when to start migraine prevention, which medications to choose, and how to manage special populations.
By: Marco Meglio
The phase 3 Aspire study of apazunersen did not meet its primary cognition end point or key secondary end point in Angelman syndrome.
By: Aaron Zelikovich, Marco Meglio
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Aaron Zelikovich, MD. [LISTEN TIME: 18 minutes]
By: Marco Meglio, Ahmet Hoke
Episode 1 features a conversation with Ahmet Hoke, MD, PhD, of Johns Hopkins Medicine, discussing the clinical debate behind keeping animal models for neuropathy research vs switching to induced pluripotent stem cell models.
The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare autoimmune disease.
By: Marco Meglio
The AAN and AHS have replaced their 2012 migraine prevention guideline with new, evidence-graded recommendations, giving neurologists clearer direction on when to start preventive therapy, how to choose among older and newer options, and how to adjust treatment for specific patients.
